The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Last month, the UK Government published its long-awaited 10-Year Health Plan, with one of its three key shifts being the move ...

Through a US$ 29 million grant, South Africa will receive enough medicine to provide HIV prevention to 450 000 people at high ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...

BIC/TAF/FTC demonstrated a stronger long-term immunologic response than DTG/TDF/FTC in patients with HIV who had low CD4+ counts.

There was no significant difference in virologic efficacy through 96 weeks in adults with HIV who switched to DTG/3TC vs continued BIC/FTC/TAF.

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...